Maurizio Martelli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study	ADVANCES IN HEMATOLOGY	2022
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design	LEUKEMIA & LYMPHOMA	2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents	CURRENT CANCER DRUG TARGETS	2022
Reduced Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) colonization in a hematological-emergency setting during the coronavirus disease 2019 (COVID-19) pandemic	INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY	2022
Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL	BREAST	2022
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors	JOURNAL OF CLINICAL MEDICINE	2022
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions	CURRENT HEMATOLOGIC MALIGNANCY REPORTS	2022
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors	CURRENT OPINION IN ONCOLOGY	2022
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)	HEMATOLOGICAL ONCOLOGY	2022
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges	INTERNATIONAL JOURNAL OF HEMATOLOGY	2022
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement	HEMATOLOGICAL ONCOLOGY	2022
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort	BLOOD ADVANCES	2022
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2022
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement	HEMATOLOGICAL ONCOLOGY	2022
Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment	CANCERS	2022
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	EXPERT REVIEW OF HEMATOLOGY	2022
Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients	SUPPORTIVE CARE IN CANCER	2022
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study	HEMATOLOGICAL ONCOLOGY	2022
Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study	BLOOD	2022